Multiple event activation of a generic prodrug trigger by antibody catalysis.
about
Rational protein design: developing next-generation biological therapeutics and nanobiotechnological toolsAn active immunization approach to generate protective catalytic antibodiesPivalase catalytic antibodies: towards abzymatic activation of prodrugs.Recombinant antibodies: a novel approach to cancer diagnosis and therapy.Synthesis of an organoinsulin molecule that can be activated by antibody catalysis.Human leukocyte differentiation antigens as therapeutic targets: the CD molecules and CD antibodies.Reactivity of Biliatresone, a Natural Biliary Toxin, with Glutathione, Histamine, and Amino Acids.Breaking the one antibody-one target axiom.Chemically programmed monoclonal antibodies for cancer therapy: adaptor immunotherapy based on a covalent antibody catalyst.Synthesis of the next-generation therapeutic antibodies that combine cell targeting and antibody-catalyzed prodrug activation.In vivo activity in a catalytic antibody-prodrug system: Antibody catalyzed etoposide prodrug activation for selective chemotherapyStimulus-controlled delivery of drugs and genes.Prodrugs of dynemicin analogs for selective chemotherapy mediated by an aldolase catalytic Ab.Instant immunity through chemically programmable vaccination and covalent self-assembly.Studies toward the duocarmycin prodrugs for the antibody prodrug therapy approach.Self-immolative spacers: kinetic aspects, structure-property relationships, and applications.Expanding the concept of chemically programmable antibodies to RNA aptamers: chemically programmed biotherapeutics.Real-time monitoring of drug release.New daunomycin-oligoarginine conjugates: synthesis, characterization, and effect on human leukemia and human hepatoma cells.Chemically Programmed Antibodies AS HIV-1 Attachment Inhibitors.Preparation and activities of macromolecule conjugates of the CCR5 antagonist Maraviroc.Serum albumin-catalyzed trigger system by using a tandem kemp elimination/beta-elimination reaction.
P2860
Q28250420-E5E98255-D934-408C-A287-CFF1271D493DQ28363317-CB475BCE-FAAC-4B1C-B224-743F23DAE234Q32051466-8D8CE861-6F1A-4275-9DC1-EFA8AD63AFD1Q33181384-01D1CE77-9C05-4813-A45A-B7591673D8F4Q33949800-1122C582-19F5-4EB8-900E-8972BC91F730Q34451956-66B4EC63-7B3A-443F-A3F6-C1C4835D9BA3Q34506878-CBDCD9F4-9077-4B9F-A724-3E3B7FA8A49CQ34715264-3CFFFA23-10FF-45D4-88A9-67D811A9370AQ34983092-98B470AA-642D-4A5C-88D5-57FB7C0EAC60Q35720193-F55EDE39-3FC3-4283-A0E3-31F5C832BB85Q36314064-77F5E940-17A5-40E5-9617-686EBC7F02F3Q36316864-CAEFA567-C5E6-4F77-89F5-EF8247D8F36FQ36853874-36736782-5C48-4EEA-A400-BD2F8C425413Q37114234-282E44CB-33CE-451F-9668-E870A8573BCEQ37401199-2A83CDF1-2075-4A7E-BEC1-6280F9CED2DBQ38520280-CA5F9749-B925-4AA1-A7B8-BC2E3DC29AFCQ39678049-CAFFDE58-CC95-40E5-B542-10FD2A8293FDQ39753844-5B3C4094-0CD8-481A-A809-1DBA5E98EACEQ39838948-6DDB6C38-4DF6-4490-8EA0-6BC800387C84Q41585863-4147A6F6-0305-496D-B73F-35190D86A1B5Q41963164-ABEF2A24-068C-4C92-B4E1-169548DA805FQ46413124-02FB11B4-5E1F-44A3-9DE2-A5F6CD7D3E08
P2860
Multiple event activation of a generic prodrug trigger by antibody catalysis.
description
1999 nî lūn-bûn
@nan
1999年の論文
@ja
1999年学术文章
@wuu
1999年学术文章
@zh-cn
1999年学术文章
@zh-hans
1999年学术文章
@zh-my
1999年学术文章
@zh-sg
1999年學術文章
@yue
1999年學術文章
@zh
1999年學術文章
@zh-hant
name
Multiple event activation of a generic prodrug trigger by antibody catalysis.
@ast
Multiple event activation of a generic prodrug trigger by antibody catalysis.
@en
type
label
Multiple event activation of a generic prodrug trigger by antibody catalysis.
@ast
Multiple event activation of a generic prodrug trigger by antibody catalysis.
@en
prefLabel
Multiple event activation of a generic prodrug trigger by antibody catalysis.
@ast
Multiple event activation of a generic prodrug trigger by antibody catalysis.
@en
P2093
P2860
P356
P1476
Multiple event activation of a generic prodrug trigger by antibody catalysis.
@en
P2093
P2860
P304
P356
10.1073/PNAS.96.12.6925
P407
P577
1999-06-01T00:00:00Z